Validated A549 Xenograft Model:
Subcutaneous And Metastatic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Non-small cell lung cancer (NSCLC) and Xenografts

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases, and includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Xenograft models, which can involve implanting human NSCLC cells into immunodeficient mice, are widely used to study tumor biology and assess the efficacy of anticancer therapies in a physiologically relevant *in vivo* environment. Using xenograft models allows for research regarding tumor growth, angiogenesis, and drug resistance; and are essential in facilitating preclinical evaluations of novel targeted and immunotherapeutic treatments for NSCLC.

A549 Cell Line

The A549 cell line, derived from a 58-year-old Caucasian male with pulmonary adenocarcinoma in 1972, is a widely used model for studying non-small cell lung cancer (NSCLC) and lung-related diseases such as allergies, asthma, and respiratory infections. It has been pivotal in research investigating tumor metastasis, with studies demonstrating that A549 xenografts, when implanted into the liver or subcutaneously in nude mice, exhibit spontaneous metastasis, making it a valuable tool for evaluating cancer progression and therapeutic interventions. The A549 xenograft model has been employed in several studies to assess the effects of novel treatments, including myricanol, vasostatin, and BrP-LPA, and is frequently used for evaluating the efficacy of existing NSCLC therapies like erlotinib, gefitinib, and paclitaxel, due to its overexpression of EGFR and HER-2.

Altogen Labs Validated A549 Xenograft Model

In this preclinical study, A549 cancer cells are prepared under aseptic conditions and assessed for viability (98-99%) using assays such as flow cytometry. The cells are then injected subcutaneously into the hind legs of 10–12-week-old athymic BALB/C or NOD/SCID mice, with each injection containing 1 million cells mixed with matrigel. Tumors are monitored for growth using digital calipers and mouse weights are recorded regularly; once tumors reach 75-150 mm^3, animals are randomized into treatment groups, and tumor measurements are taken daily. At the study's conclusion, necropsy is performed, and tumors are excised, weighed, and analyzed histologically or for gene expression using techniques like RNA-later stabilization or snap freezing for further molecular analysis.



Figure 1. Tumor growth of A549 cells as subcutaneous xenograft *in vivo*, tumor volume, mean values +/- SEM.

Subcutaneous A549 Lung Cancer Xenograft Model

The subcutaneous A549 xenograft model is commonly used to study human lung adenocarcinoma by implanting A549 cells, a non-small cell lung cancer cell line, into the subcutaneous tissue of immunocompromised mice. This model allows for the preclinical evaluation of tumor growth, metastasis, and the efficacy of various therapeutic agents in a controlled *in vivo* environment. Additionally, it provides insights into the molecular mechanisms underlying tumor progression and the response to treatment.

Metastatic A549 Xenograft Model

The metastatic A549 xenograft model involves the injection of A549 tumor cells into immunocompromised mice, either orthotopically into the lungs or via tail vein, to study the process of metastasis in non-small cell lung cancer (NSCLC). This model enables the evaluation of metastatic spread to distant organs, such as the liver, bones, and brain, offering insights into the molecular mechanisms driving cancer dissemination. It is widely used to test the efficacy of anti-metastatic therapies and to investigate the role of specific genes or signaling pathways in tumor metastasis.

Orthotopic A549 Xenograft Model

The orthotopic A549 xenograft model involves the injection of A549 lung cancer cells into the right lung of BALB/c nude mice to establish a more clinically relevant representation of human lung cancer. This model is highly efficient, with a 90% tumor formation rate and a median survival time of 30.7 days, while also exhibiting 100% tumor metastasis. Spiral CT imaging is utilized to dynamically monitor tumor growth, providing a valuable tool for evaluating tumor progression and therapeutic responses in a natural lung environment.

Case Study: Chemotherapy Validation in A549 Human Lung Cancer Xenograft Model

Foster, K. A., *et al.*, investigated A549 cells as a model for drug metabolism, in a study published by *Experimental Cell Research* journal. A549 cells were subcutaneously injected into the left flank of immunocompromised mice. The paclitaxel treatment was 20 mg/kg, IP twice/week. Tumor volume was measured twice a week using calipers. At the end of the study, mice were sacrificed, tumors were excised and weighed.



Figure 2. Tumor weight of A549 cells in vehicle control group mice and paclitaxel treated mice at the end of the study.

Betulin-Aldehyde Enhances Autophagic Activity and Inhibits Oncogenic Activity in A549 Cells

In a different study conducted by Huang, Ph. *et al*, published in *Scientific Reports* journal investigated the potential of betulin-aldehyde to inhibit the oncogenic activity of A549 cells by modulating intracellular autophagy, a cellular process involved in the degradation and recycling of damaged or unnecessary components. Researchers evaluated the effects of betulin-aldehyde on autophagic flux in A549 cells which yielded results that demonstrated that as the concentration of betulin-aldehyde increased, there was a corresponding and sustained rise in the formation of autophagosomes; vesicles that play a key part in autophagy. This observation indicated that betulin-aldehyde enhanced the autophagic activity within the cells in a concentration dependent manner.



Figure 3. A549 cells implanted subcutaneously in nude mice were treated with betulin-aldehyde to evaluate its effects.

Additional Case Study: Immune Modulation of Tumor Growth in A549 Xenograft Models in Humanized Mice

Additionally, in a study conducted by Rios-Doria J *et al*, published by *Journal for Immunotherapy of Cancer*, researchers evaluated the growth and immune cell composition of 10 xenograft tumor models implanted in CD34+ humanized mice. Researchers were able to determine that although the A549 xenograft model grew robustly in humanized mice, its growth rate was approximately twice as slow in immunodeficient mice, suggesting a role for the humanized immune system in modulating tumor behavior.

Impact of A549 Lung Cancer Cells on Mesenchymal Stem Cell Phenotype: Implications for Regenerative Therapy in Cancerous Environments

Mesenchymal stem cells (MSCs) have shown promise in regenerative therapies, but their interactions with cancer cells remain unclear, particularly in cancer patients. A549 lung cancer cells can influence the MSC phenotype by increasing the expression of proto-oncogenes CEA and EpCAM. Results showed that co-culturing MSCs with A549 cells led to a significant increase in EpCAM expression after 72 hours, as well as a steady increase in CEA expression over 120 hours. These findings suggest that the cancerous microenvironment may alter MSC behavior, potentially impacting processes like proliferation and metastasis, and raising concerns about the safety of MSC transplantation in cancer patients, particularly for tissue repair in conditions like radiation pneumonitis.

The A549 xenograft model offers a range of experimental options for studying lung cancer therapies, which are available at Altogen Labs. These include assessments of tumor growth delay (TGD) or inhibition (TGI), with varying dosing frequencies and administration routes, such as intravenous, intratracheal, subcutaneous, intratumoral, oral gavage, and more advanced methods like micro-injection and pump-controlled IV injection. Additionally, the model can be adapted for safety toxicology, ADME (absorption, distribution, metabolism, excretion) studies, immunohistochemistry for tumor analysis, and the evaluation of alternative cell engraftment sites, such as orthotopic transplantation or tail vein injection for metastasis. Blood chemistry, toxicity, survival, and positive control groups using standard chemotherapy compounds further support comprehensive preclinical evaluation.

References:

Foster, K. A., Oster, C. G., Mayer, M. M., Avery, M. L., & Audus, K. L. (1998). Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. *Experimental cell research*, *243*(2), 359–366. https://doi.org/10.1006/excr.1998.4172

Jun, J.H., Shim, JK., Oh, J.E. *et al*. Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model. *Sci Rep* 13, 12471 (2023). https://doi.org/10.1038/s41598-023-39704-3

Huang, Ph., Duan, Xb., Tang, Zz. *et al.* Betulinaldehyde exhibits effective anti-tumor effects in A549 cells by regulating intracellular autophagy. *Sci Rep* **13**, 743 (2023). https://doi.org/10.1038/s41598-023-27580-w

Liu X *et al*. Establishment of an orthotopic lung cancer model in nude mice and its evaluation by spiral CT. *J Thorac Dis* 2012;4(2):141-145. DOI: 10.3978/ j.issn.2072-1439.2012.03.04

A549 Xenograft Model. https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/a549-xenograft-model/

Rios-Doria J, Stevens C, Maddage C, Lasky K, Koblish HK. Characterization of human cancer xenografts in humanized mice. *J Immunother Cancer.* 2020 Mar;8(1):e000416. doi: 10.1136/jitc-2019-000416. PMID: 32217760; PMCID: PMC7174072.

Keywords: A549, xenograft, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, tumor